Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01559103 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01559103: Clinical Trial Phase 1 study, sponsored by Novo Nordisk A/S.
NCT01559103 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01559103, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients
Interventions
- BIOLOGICAL MEDI5117
- BIOLOGICAL MEDI5117 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-05-31 |
| Est. Completion | 2014-02-28 |
| Phase | Phase 1 |
Why NCT01559103 stopped before completion
NCT01559103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which MEDI5117 is the first listed.
NCT01559103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01559103 about?
NCT01559103 is a clinical study titled "Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients". Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients
What is the current status of trial NCT01559103?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2012-05-31. Estimated completion is 2014-02-28.
What interventions are being tested in trial NCT01559103?
The interventions under investigation include: MEDI5117 (BIOLOGICAL), MEDI5117 Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT01559103?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01559103's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI